Bufalin Inhibits Melanoma Progression and Endothelial Angiogenic Phenotypes via AKT Signaling
Xiao xuan Zhao, Ming xin Li, Jiang xue Qu · 2026
Read Bufalin Inhibits Melanoma Progression and Endothelial Angiogenic Phenotypes via AKT Signaling by Xiao xuan Zhao, Ming xin Li, Jiang xue Qu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13552026.txt.
Description
Xiaoxuan Zhao, Mingxin Li, and Jiangxue Qu test, in a 2026 study, whether bufalin, a compound from toad venom used in traditional medicine, can slow melanoma and starve its blood supply. The drug is known against several tumors, but its action in melanoma was largely unmapped.
In dishes, bufalin cut melanoma cell growth, froze the cell cycle before division, and triggered cell death. It also blunted the growth, movement, and tube-building of vein lining cells, the stuff of new tumor vessels. Computer analysis pointed at the PI3K-AKT pathway, and docking suggested a fit. Mouse tumors grown from human cells tested the effect in a living body.
Catalog record
| CREATOR | Xiao xuan Zhao, Ming xin Li, Jiang xue Qu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |